Consistently, in drug-naïve T2D patients from the ChiHOPE cohort, lower baseline plasma GPX3 levels were correlated with more adverse metabolic profiles, including lower high-density lipoprotein cholesterol (HDL-C), and higher insulin resistance, circulating lipids and obesity (Fig. 2a, Table S8). Here, GPX3 is linked to obesity disorder.